Moprolol

Cat. No.:	HY-108306
CAS No.:	5741-22-0
Molecular Formula:	$C_{13}H_{21}NO_3$
Molecular Weight:	239.31
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Moprolol ((±)-Moprolol) is an beta-adrenergic receptor blocker, which can be used for research in essential hypertension[1][2][3].
IC_{50} & Target	Beta-1 adrenergic receptor
In Vitro	l-Moprolol is a β-blocker L-enantiomer with low negative inotropic activity and mild intrinsic sympathetomimetic activity, which can be used effectively in systemic hypertension studies. In primary open Angle glaucoma (POAG) or ocular hypertension (OHT) models, the topical application of l-Moprolol can reduce intraocular pressure (IOP) as effectively as tiolol, and has emerged as a promising compound for the inhibition of glaucoma due to its lack of activity on bronchial muscles[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Borowiecki P, et al. Development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. A case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol. RSC Adv. 2022 Aug 10;12(34):22150-22160.

[2]. Liu J, et al. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther. 2006 Jul;80(1):23-32.

[3]. Rossetti L, et al. The efficacy of the combination of l-moprolol and dipivefrin in reducing the intraocular pressure in primary open-angle glaucoma or in ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 1994 Nov;232(11):670-4.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA